Absci Corp., a clinical-stage biopharmaceutical company based in Vancouver, Washington, said it plans to initiate a Phase 2 trial of ABS-201 for endometriosis in mid-2027.
The trial, dubbed STORYLINE, will be a double-blind, randomized, placebo-controlled study enrolling approximately 150 patients across 10 or more countries, subject to protocol finalization and regulatory clearance. The design will test two or three dose levels, with the exact regimen to be confirmed after reviewing data from the ongoing HEADLINE trial, which is currently generating safety, tolerability and pharmacokinetic data for ABS-201.
Eligible participants must have surgically diagnosed endometriosis and moderate to severe endometriosis-associated pain. Efficacy will be measured through reductions in dysmenorrhea and non-menstrual pelvic pain reported via patient-reported outcome measures.
Endometriosis affects approximately one in ten women of reproductive age globally.
ABS-201 is an investigational anti-prolactin receptor antibody engineered using Absci’s generative AI platform. The asset is also being investigated for pattern hair loss.
"We are developing ABS-201 because we believe prolactin receptor blockade offers a fundamentally different, non-hormonal approach that may fulfill the substantial unmet clinical need facing these patients," said Ransi Somaratne, chief medical officer and head of R&D at Absci.
Shares of Absci trade on NASDAQ under the ticker ABSI.
